Harvard Bioscience Lifts Full-Year Outlook as Q2 Revenue Climbs 11%
HBIO sits 63% above its 52-week low of $3.755.
Summary
Harvard Bioscience reported Q2 2026 revenue of $22.7M, up 11% YoY, and raised full-year revenue guidance. Net loss narrowed slightly, but high debt costs and cash burn persist.
Key Events · Earnings and Guidance · HBIO
-
Q2 Revenue Beats, Guidance Raised
Revenue of $22.7M grew 11% YoY, driven by CRO and Asia Pacific demand. Full-year revenue guidance was raised, signaling confidence in the recovery.
-
Net Loss Narrows
Q2 net loss was $2.9M ($0.64/share) vs. $2.3M loss a year ago. The improvement reflects higher sales and lower amortization, partially offset by higher interest expense.
-
Cash Burn Continues
Cash fell to $6.5M from $8.6M at year-end. Operating cash flow was negative $0.3M for the first half, with inventory build and restructuring costs weighing.
-
Debt Costs Remain High
Total debt stands at $36.7M with an effective interest rate of 17.9%. Interest expense jumped 79% YoY to $1.8M in Q2, consuming a significant portion of gross profit.
Analysis · HBIO · Industrial Applications And Services
Harvard Bioscience posted Q2 revenue of $22.7 million, an 11% year-over-year gain, and raised its full-year revenue forecast. Cash burn remains a concern, with only $6.5 million on hand against $36.7 million in debt that carries a steep 17.9% effective interest rate. The Project Viking restructuring is proceeding as planned, though it added $0.3 million in charges this quarter. While the raised guidance points to strengthening demand, the balance sheet continues to look strained.
At the time of this filing, HBIO was trading at $6.13 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $27.6M. The 52-week trading range was $3.76 to $9.40. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.